V1RC Inhibitors
Chemical inhibitors of V1RC operate through various molecular mechanisms to disrupt the normal function of this receptor protein. Suramin, for instance, can directly interfere with the receptor-ligand interactions essential for V1RC function by binding to the receptor or its ligand, thereby obstructing the signal transduction process. Amiloride, known for its ion channel inhibition properties, can alter the electrochemical signal transduction by inhibiting channels associated with V1RC. In a similar vein, PD 169316 and SB 203580 specifically target p38 MAP kinase activity, which is a crucial component in the signaling pathways that V1RC may be involved in. The inhibition of this kinase by these chemicals results in a blockade of the downstream phosphorylation events that are necessary for V1RC-mediated signal transduction.
Further along the signaling cascade, LY 294002 and Wortmannin exert their effects by inhibiting phosphoinositide 3-kinases (PI3K), which are upstream regulators of many signaling pathways including those involving V1RC. This inhibition can prevent the activation of downstream components that are pivotal for V1RC function. The Src family kinases, which can be inhibited by PP2, are another group of enzymes that can phosphorylate V1RC or its associated proteins, thereby modulating its activity. Additionally, Gefitinib's selective inhibition of the epidermal growth factor receptor (EGFR) tyrosine kinase can have a downstream impact on V1RC if its signaling is connected to EGFR pathways. U0126 and PD 98059 target MEK1/2, which are part of the MAPK/ERK pathway, and their inhibitory action can lead to decreased V1RC activity if the protein is regulated by this pathway. Lastly, SP600125 targets the JNK signaling molecules which can impact V1RC activity if it is dependent on the pathways regulated by these kinases.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suramin sodium | 129-46-4 | sc-507209 sc-507209F sc-507209A sc-507209B sc-507209C sc-507209D sc-507209E | 50 mg 100 mg 250 mg 1 g 10 g 25 g 50 g | $152.00 $214.00 $728.00 $2601.00 $10965.00 $21838.00 $41096.00 | 5 | |
Suramin, a hexasodium salt, can inhibit the V1RC protein by disrupting cell surface receptor interactions. It is known to interfere with the binding of various growth factors to their cellular receptors, and in the context of V1RC, it could hinder the interaction of ligands specific to this receptor, leading to functional inhibition. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $296.00 | 7 | |
Amiloride functions as a diuretic by inhibiting epithelial sodium channels. Its ability to inhibit ion channels can extend to the V1RC protein if V1RC is involved in ion transport or electrochemical signal transduction, thereby impairing the receptor's function. | ||||||
PD 169316 | 152121-53-4 | sc-204168 sc-204168A sc-204168B sc-204168C | 1 mg 5 mg 10 mg 25 mg | $88.00 $156.00 $281.00 $461.00 | 3 | |
PD 169316 is a selective inhibitor of p38 MAP kinase, which is involved in cellular responses to stress and inflammation. If V1RC participates in signaling pathways downstream of p38 MAP kinase, PD 169316 can inhibit those pathways, leading to a reduction in V1RC protein function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 specifically inhibits p38 MAP kinase activity. By blocking this kinase, the chemical can prevent the phosphorylation and activation of downstream targets, which may include V1RC or its associated signaling components, resulting in functional inhibition of the V1RC protein. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). If the V1RC protein operates downstream of PI3K or within the PI3K pathway, the inhibition of PI3K by LY 294002 would disrupt V1RC protein signaling and function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. Src kinases can phosphorylate a variety of substrates, including receptor proteins. Inhibition of Src kinases by PP2 can result in the functional inhibition of the V1RC protein if V1RC is a substrate for Src kinase or if Src kinase activity modulates V1RC signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib selectively inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase. If V1RC signaling is intertwined with EGFR signaling pathways, inhibiting EGFR with Gefitinib can result in a downstream reduction in V1RC protein activity, effectively inhibiting its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which are upstream of extracellular signal-regulated kinases (ERK1/2). By blocking MEK1/2, U0126 can inhibit ERK signaling pathways. If V1RC protein is functionally regulated by the ERK pathway, inhibition by U0126 would result in decreased V1RC protein activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 selectively inhibits MEK, which is part of the MAPK/ERK pathway. Inhibition of MEK by PD 98059 would block the phosphorylation and activation of ERK, potentially leading to functional inhibition of the V1RC protein if it is regulated by or associated with the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the c-Jun N-terminal kinase (JNK). JNK participates in various cellular processes, including the regulation of some receptor proteins. Inhibition of JNK by SP600125 could lead to functional inhibition of the V1RC protein if V1RC signaling is JNK-dependent. | ||||||